Brief: Cassava Sciences Completes Patient Dosing In A Randomized Controlled Trial Of Simufilam In Alzheimer’S Disease

Filana Therapeutics

11/05/2023 16:24

May 11 (Reuters) - Cassava Sciences Inc  SAVA.O :
    * CASSAVA SCIENCES COMPLETES PATIENT DOSING IN A RANDOMIZED
CONTROLLED TRIAL OF SIMUFILAM IN ALZHEIMER’S DISEASE
    * CASSAVA SCIENCES INC - EXPECTS TO ANNOUNCE CMS TOP-LINE
DATA IN
Q3 2023

Source text for Eikon:  ID:nGNX3j8f 

 ((Reuters.Briefs@thomsonreuters.com;))